Evidence mapPaperPMID 42072634Full record

ReviewBiomolecules2026

The Therapeutic Potential of Exosomes in Ocular Surface Diseases.

Lanxin Hu, Hongyu Duan, Yu Zhang, Liang Yang, Kyung Chul Yoon, Zihan Shen, Zekai Li, Baikai Ma, Hong Qi

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lanxin HuBeijing Key Laboratory of Restoration of Damaged Ocular Nerve, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.
Hongyu DuanBeijing Key Laboratory of Restoration of Damaged Ocular Nerve, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.
Yu ZhangBeijing Key Laboratory of Restoration of Damaged Ocular Nerve, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.
Liang YangBeijing Key Laboratory of Restoration of Damaged Ocular Nerve, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.
Kyung Chul YoonDepartment of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea.ORCID 0000-0002-2788-1851
Zihan ShenInstitute of Medical Technology, Peking University Health Science Center, Beijing 100191, China.
Zekai LiInstitute of Medical Technology, Peking University Health Science Center, Beijing 100191, China.
Baikai MaBeijing Key Laboratory of Restoration of Damaged Ocular Nerve, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.
Hong QiBeijing Key Laboratory of Restoration of Damaged Ocular Nerve, Department of Ophthalmology, Peking University Third Hospital, 49 North Garden Rd., Haidian District, Beijing 100191, China.

Funding

Beijing Municipal Natural Science Foundation F251030Innovation and Transformation Fund of Peking University Third Hospital BYSYZHKC2023110National Natural Science Foundation of China 82371026TMICPKU Proof of Concept Grant CXYZ-2025-102
6 · The paper itself

Abstract

The ocular surface system, essential for maintaining visual function, is highly susceptible to a range of ocular surface diseases (OSDs) that significantly impair patients' quality of life. Current treatments for OSDs often face limitations including low bioavailability, A lack of targeted delivery, and an inadequate capacity to fully address the complex pathophysiology involving inflammation, oxidative stress, and impaired tissue repair. In recent years, exosomes have emerged as promising cell-free therapeutic platforms for OSDs. This review evaluates their therapeutic potential across the OSD spectrum, focusing on three key aspects: mechanisms-modulation of inflammation, oxidative stress, and tissue repair via bioactive cargo; applications-preclinical therapeutic effects in dry eye disease, corneal injury, keratitis, and transplant rejection; and optimization strategies-engineering approaches and biomaterial integration to enhance stability, targeting, and ocular retention. We also discuss critical challenges in standardization, scalable production, and clinical translation, highlighting future directions for exosome-based OSD therapies.

Indexed as

Corneal DiseasesDry Eye SyndromesExosomesEye DiseasesAnimalsHumansOxidative Stressexosomesextracellular vehiclesocular surface diseases

Identifiers

PMID42072634
PMCPMC13113474

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.